Injection Abscess in Athletes: Causes and the Link to Performance Drugs
An abscess at an injection site is one of the most common physical complications seen in people who inject performance-enhancing drugs outside of medical supervision. It can start as mild soreness and progress to a hospital admission within days. Our editorial team explains how these infections develop, why non-prescribed products carry particular risk and what signs mean you should not wait to see a doctor.
What an injection abscess is
An abscess is a walled-off collection of pus inside tissue. It forms when bacteria get past the skin barrier and the immune system tries to contain them. White blood cells, dead tissue and bacteria accumulate in a cavity, which becomes swollen, hot, red and painful.
After an intramuscular injection, the abscess may sit deep in muscle, which makes it harder to see than a skin boil. The surface can look only mildly red while a large pocket develops underneath. That is why deep, throbbing pain that worsens over several days deserves attention even when the skin looks fairly normal.
The most frequent culprit is Staphylococcus aureus, including methicillin-resistant strains (MRSA) that are common in US communities. Streptococci and, less often, other organisms can also be involved, particularly when products are contaminated during manufacturing.
A sterile abscess is a related but distinct problem: an inflammatory reaction to the injected oil or substance itself, without infection. It can look similar, and only a clinician can tell the two apart, sometimes with imaging or a sample of the fluid.
Why performance drugs raise the risk
In medical practice, intramuscular injections are given with sterile, pharmaceutical-grade products, and serious infections are rare. The situation changes when people inject anabolic steroids, peptides or other substances obtained outside the regulated supply chain.
Underground products are made without FDA oversight. Analyses of seized and purchased samples have repeatedly found wrong concentrations, substituted ingredients and signs of poor sterility. Oil-based solutions made in improvised conditions can carry bacteria or particles straight into deep tissue.
Case reports, such as the one by Rich et al. (1999), described abscesses requiring surgical drainage after steroid injection. Evans (2004) reviewed local complications of self-administered steroid injections and listed abscesses, nerve injury and muscle inflammation among them.
Shared vials or equipment add another layer of danger. Hope et al. (2013) studied men in the UK who inject image- and performance-enhancing drugs and found that this group also faces measurable rates of blood-borne viruses such as hepatitis B, hepatitis C and HIV, as well as injection-site problems.
The Endocrine Society scientific statement (Pope et al., 2014) noted that injection-related infections are part of the broader pattern of harm linked to non-medical use of performance-enhancing drugs, alongside cardiovascular, endocrine and psychiatric effects.
Warning signs and how fast it can escalate
Some soreness after any intramuscular injection is common and usually fades within a day or two. An infection behaves differently: pain grows instead of easing, and local signs spread.
- Increasing pain, swelling or hardness after the first 24–48 hours
- Redness or warmth that expands beyond the injection area
- A soft, fluctuant lump or drainage of pus
- Fever, chills, rapid heartbeat or feeling generally unwell
- Red streaks running from the site, numbness or severe pain out of proportion to appearance
Fever with a racing heart, confusion or low blood pressure can indicate that infection has entered the bloodstream. Severe pain with rapidly spreading changes can be a sign of necrotizing soft-tissue infection. Both are emergencies: call 911 or go to an emergency department.
Infections in the buttock or thigh can also involve deep structures, including the hip region. Delays in care raise the chance of complications that need surgery and long recovery.
Diagnosis and treatment in US practice
A clinician will examine the area and may order an ultrasound to see whether there is a fluid collection and how deep it lies. For deep or complicated cases, CT or MRI may be used. Blood tests help assess the body's inflammatory response.
According to the Infectious Diseases Society of America guideline (Stevens et al., 2014), the main treatment for an abscess is incision and drainage. Antibiotics are added depending on size, severity, signs of systemic illness and the local likelihood of MRSA.
| Situation | Typical approach | Setting |
|---|---|---|
| Small superficial abscess, no fever | Drainage, wound care, possible oral antibiotics | Urgent care or primary care |
| Larger or deep abscess | Imaging, surgical drainage, antibiotics | Emergency department, surgery |
| Fever, rapid pulse, spreading redness | IV antibiotics, blood cultures, admission | Hospital |
| Suspected necrotizing infection | Emergency surgery | Hospital, immediately |
Squeezing or trying to open the lump at home is risky. It can push bacteria deeper and delay proper care. It is also important to tell the clinician honestly what was injected; that information changes testing and treatment, and medical confidentiality rules protect the conversation.
Clinicians may also recommend screening for hepatitis B, hepatitis C and HIV when non-sterile injection is part of the history, and vaccination against hepatitis B if not already immune.
Reducing harm and the bigger picture
The safest way to avoid an injection abscess linked to performance drugs is not to use non-prescribed injectable substances. Prescription medications, including testosterone for diagnosed hypogonadism, should come from licensed pharmacies and be used under a physician's supervision.
For people who are already using these substances, honest contact with health services matters. Many US cities have syringe services programs that offer sterile supplies, testing and referrals without judgment. A primary care physician can monitor blood work and check injection sites.
Recurring abscesses are a signal that something in the chain is not working: product quality, equipment, skin hygiene or immune status. They should not be treated as an unavoidable cost of training.
Beyond infections, an abscess is often the first contact a user has with the medical system. Clinicians can use that moment to assess blood pressure, lipids, hematocrit and mental health, which often reveal problems that are more serious in the long term than the abscess itself.
Conclusions of the editorial team
Injection abscesses in athletes are closely tied to non-prescribed, often underground products and to non-sterile conditions.
Pain that worsens after the first day or two, spreading redness, a fluctuant lump or fever all call for prompt medical evaluation; signs of sepsis or severe spreading pain are emergencies.
Drainage is the cornerstone of treatment, with antibiotics as needed. Home attempts to open an abscess are dangerous.
For further reading, see our articles on hematocrit and blood viscosity in steroid users, how to talk to your doctor about performance drug use, and the risks of counterfeit peptides.
References
- Rich JD, Dickinson BP, Flanigan TP, Valone SE. Abscess related to anabolic-androgenic steroid injection. Med Sci Sports Exerc. 1999;31(2):207–209.
- Evans NA. Local complications of self administered anabolic steroid injections. Br J Sports Med. 2004;38(3):340–341.
- Hope VD, McVeigh J, Marongiu A, et al. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. BMJ Open. 2013;3(9):e003207.
- Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10–e52.
- Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
